





## Structural Show and Tell

Neil P. Fam MD MSc FRCPC

Director, Structural Heart Program


Schroeder Chair in Structural and Valve Innovation

St. Michael's



## **Disclosures**

Consultant-Edwards, Abbott, Medtronic, Cardiovalve



Heart in diastole: viewed from base with atria removed

## **Objectives**

1. Discuss the recent advances in TAVI, mitral and tricuspid intervention

2. Review interesting cases

#### The NEW ENGLAND JOURNAL of MEDICINE


#### ORIGINAL ARTICLE


## Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients

M.J. Mack, M.B. Leon, V.H. Thourani, R. Makkar, S.K. Kodali, M. Russo, S.R. Kapadia, S.C. Malaisrie, D.J. Cohen, P. Pibarot, J. Leipsic, R.T. Hahn, P. Blanke, M.R. Williams, J.M. McCabe, D.L. Brown, V. Babaliaros, S. Goldman, W.Y. Szeto, P. Genereux, A. Pershad, S.J. Pocock, M.C. Alu, J.G. Webb, and C.R. Smith, for the PARTNER 3 Investigators\*

# Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients Jeffrey J. Popma, M.D., G. Michael Deeb, M.D., Steven J. Yakubov, M.D., Mubashir Mumtaz, M.D., Hemal Gada, M.D., Daniel O'Hair, M.D., Tanvir Bajwa, M.D., John C. Heiser, M.D., William Merhi, D.O., Neal S. Kleiman, M.D., Judah Askew, M.D., Paul Sorajja, M.D., Joshua Rovin, M.D., Stanley J. Chetcuti, M.D., David H. Adams, M.D., Paul S. Teirstein, M.D., George L. Zorn III, M.D., John K. Forrest, M.D., Didier Tchétché, M.D., Jon Resar, M.D., Antony Walton, M.D., Nicolo Piazza, M.D., Ph.D., Basel Ramlawi, M.D., Newell Robinson, M.D., George Petrossian, M.D., Thomas G. Gleason, M.D., Jae K. Oh, M.D., Michael J. Boulware, Ph.D., Hongyan Qiao, Ph.D., Andrew S. Mugglin, Ph.D., and Michael J. Reardon, M.D., for the Evolut Low Risk Trial Investigators\*

The NEW ENGLAND IOURNAL of MEDICINE





## Morphological Features of Aortic Valve Stenosis or Regurgitation

#### Calcific Aortic Valve Stenosis

1- Nodular calcific deposits on aortic side





#### Aortic Valve Regurgitation

- 1- Minimal or absent cusp calcification
- 2- Dilated aortic root
- 3- Frequent coexistence of dilated ascending aorta





### Technical Challenges of TAVR in Aortic Valve Regurgitation

Suboptimal Fluoroscopic Visualization of the Native Valve

Insufficient Anchoring and Sealing of the Transcatheter Device

Risk of Misplacement and Migration of the Device

Risk of Residual Valvular Regurgitation

## **Dedicated TAVIs for AR**




J valve



Jena Trilogy valve

### Case

- 84M progressive NYHA 3 dyspnea, HF hospitalization
- CABG 1998 (patent LIMA-LAD, SVG to D1-OM-RCA) PCI 2011
- AF, DM, HTN, CKD
- EF 50%, severe AR, severe MR, mod TR, PA=80
- STS score 11%









## **J Valve**










18F Transfemoral system Treats up to 34mm annulus












## TEER for MR



## TEER Toolbox





## TMVRs in Trials

Intrepid (Medtronic)



Tendyne (Abbott)



M3 (Edwards)













## Case 2

#### 83 year old female with symptomatic severe MR

- NYHA III symptoms, one year history of peripheral edema, orthopnea, PND
- Severe primary MR with P3 prolapse and MAC on initial workup
- DM, HTN
- EF 45%, normal coronaries


## TEE – baseline





#### **APOLLO Trial**


Investigating TMVR System for Patients Unsuitable for Authorized Transcatheter Repair or Surgical Mitral Valve Intervention







**APOLLO TRIAL** 

Procedural imaging



# Procedural imaging







Measurements	
LVEDD	55 mm
LVESD	53 mm
LVEF	42%

 Improved to NYHA II at 1-month follow-up, gradual uptitration of GDMT

## **Current TTVI Device Landscape**




## **EVOQUE** Transcatheter Tricuspid Valve Replacement System





## **TRISCEND II: All-Cause Mortality**




fda.gov

#### Case 3

## 80 yo female w/ HFpEF and torrential TR


- struggling with tricuspid regurgitation since 2022
- Tricuspid TEER January 2023 in QC: torrential to moderate-severe
- FU February 2023: SLDA of both clips (one attached to septal, other to anterior leaflet)
- symptoms slowly progressive and currently NYHA III and peripheral edema despite diuretics

## TEE – baseline





















Tricuspid Valve	
Mechanism	Annular dilatation w/ large central coaptation gap
TVA	16.8 cm <sup>2</sup>
Mean Grad	1 mmHg (83 bpm)
Hep Veins	S flow reversal

















# Follow up TTE



## **Summary**

 Structural heart intervention continues to rapidly evolve to provide innovative catheter-based options for patients

 SMH Program uses Heart Team approach to make best decision for individual patient



## St. Michael's

Inspired Care. Inspiring Science.

#### **Structural Heart Program Referral Form**

30 Bond Street, Suite 8-003 Toronto, Ontario M5B 1W8

TEL: 416-864-5442 FAX: 416-864-5768 Email: StructuralHC@smh.ca

Jenn Holmes, RN Structural Heart Coordinator Jennifer.holmes@unityhealth.to

## **Thank You!**

neil.fam@unityhealth.to